Accurate curve fitting is central to quantifying dose–response relationships in drug discovery. However, commonly used regression-based methods are ill-suited for early prescreening assays, where measurements are sparse and experimental noise can dominate. Bayesian approaches have been developed previously, but they are rarely optimized for such data-limited, noise-prone conditions. We present BayesCurveFit, a Bayesian framework specifically designed for robust dose–response inference under data scarcity. The workflow integrates calibrated initialization, stochastic optimization, adaptive posterior sampling, and probabilistic mixture modeling within a unified Bayesian pipeline, enabling reliable parameter estimation and uncertainty quantification from few observations. By modeling residuals with a Gaussian–Laplace hybrid distribution, BayesCurveFit remains robust to outliers where ordinary least squares and conventional regression methods fail. Simulation studies and real screening benchmarks demonstrate that BayesCurveFit outperforms state-of-the-art regression-based methods in recovering true dose–response relationships under limited sampling. In addition, a Bayesian measure of significance – posterior error probability – offers interpretable probabilistic confidence for response classification. Together, these features establish a general and easy-to-use Bayesian framework for analyzing dose–response data in early screening experiments.
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
bioRxiv
- Publication date
2025-11-09
- Fields of study
Biology, Medicine, Chemistry, Computer Science
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-42 of 42 references · Page 1 of 1
CITED BY
- No citing papers are available for this paper.
Showing 0-0 of 0 citing papers · Page 1 of 1